What Makes Journey Medical Corporation (DERM) a Good Investment?

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the 12.4% return of the Russell 2000 Index ETF (IWM) and the 12.5% return for the Russell 2000 Value Index ETF (IWN). Year-to-date, the fund is up 4.9% net compared to 10.3% and 8.9% returns for the indexes, respectively. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2025.

In its third-quarter 2025 investor letter, Summers Value Partners highlighted stocks such as Journey Medical Corporation (NASDAQ:DERM). Journey Medical Corporation (NASDAQ:DERM) engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The one-month return of Journey Medical Corporation (NASDAQ:DERM) was 8.46%, and its shares gained 52.01% of their value over the last 52 weeks. On November 18, 2025, Journey Medical Corporation (NASDAQ:DERM) stock closed at $7.95 per share, with a market capitalization of $215.73 million.

Summers Value Partners stated the following regarding Journey Medical Corporation (NASDAQ:DERM) in its third quarter 2025 investor letter:

“Journey Medical develops and markets dermatology products. The company recently launched Emrosi for the treatment of rosacea. The rollout continues to be on track, with annualized sales approaching $30 million in the first six months following its launch. We believe Emrosi could exceed $100 million in peak sales based on positive physician and patient feedback. The company is positioned for profitability in 2026, supported by a scalable business model. Given ongoing consolidation in the dermatology industry, Journey may also be viewed as an attractive acquisition candidate. Our price target remains $20 per share.”

Journey Medical Corporation (NASDAQ:DERM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 4 hedge fund portfolios held Journey Medical Corporation (NASDAQ:DERM) at the end of the second quarter, compared to 6 in the previous quarter.  Journey Medical Corporation’s (NASDAQ:DERM) revenue for the third quarter of 2025 was $17.6 million compared to $14.9 million in Q3 2024. While we acknowledge the risk and potential of Journey Medical Corporation (NASDAQ:DERM) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Journey Medical Corporation (NASDAQ:DERM) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Journey Medical Corporation (NASDAQ:DERM) and shared Summers Value Fund’s views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.